NCT01569113View on ClinicalTrials.gov

Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Emergency Contraception
Interventions
DRUG

Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)

UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake

DRUG

placebo + ethinylestradiol/levonorgestrel

placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake

Trial Locations (3)

9713

Dinox, Groningen

SE-171 76

Karolinska University Hospital Solna, Stockholm

EH3 9ES

Chalmers Sexual Health Clinic, Edinburgh

Sponsors

Lead Sponsor

HRA Pharma
All Listed Sponsors
lead

HRA Pharma

INDUSTRY

NCT01569113 - Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. | Biotech Hunter | Biotech Hunter